{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:21:49Z","timestamp":1781641309645,"version":"3.54.5"},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Incidences of sexual dysfunction due to the use of 5 \u03b1\u2010reductase inhibitors have been suggested. Despite low sexual dysfunction reported in clinical trials, an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System (<jats:styled-content style=\"fixed-case\">FAERS<\/jats:styled-content>) database revealed a significant disproportionality in the reporting of sexual dysfunction with the use of finasteride. Therefore, it is likely that a similar relationship with dutasteride may exist.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether dutasteride use leads to a higher risk of sexual dysfunction compared to a baseline risk for all other drugs using the <jats:styled-content style=\"fixed-case\">FAERS<\/jats:styled-content> database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A case by non\u2010case disproportionality approach was used whereby a reporting odds ratio (<jats:styled-content style=\"fixed-case\">ROR<\/jats:styled-content>) with 95% confidence interval (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) was calculated. Cases of dutasteride\u2010associated sexual dysfunction were compared to a reference risk of sexual dysfunction for all other drugs in the database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A significant disproportionality in reporting of sexual dysfunction with the use of dutasteride was observed. The disproportionality was present for all age ranges except for 31\u201345 years where there were few overall reports of adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Limitations<\/jats:title><jats:p>Adverse events can be underreported, and selection bias is inherent in the <jats:styled-content style=\"fixed-case\">FAERS<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Dutasteride use is associated with an increase in reports of sexual dysfunction.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.14728","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T19:52:01Z","timestamp":1512157921000},"page":"1373-1376","source":"Crossref","is-referenced-by-count":8,"title":["Assessing dutasteride\u2010associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1111","volume":"32","author":[{"given":"A.K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Medicine University of Toronto School of Medicine Toronto ON Canada"},{"name":"Mediprobe Research Inc. London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Carviel","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc. London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Schulich School of Medicine and Dentistry University of Western Ontario London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.H.","family":"Shear","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Medicine Sunnybrook Health Sciences Centre University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,21]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"1","article-title":"Promising therapies for treating and\/or preventing androgenic alopecia","volume":"17","author":"McElwee KJ","year":"2012","journal-title":"Skin Ther Lett"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12060"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030330"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/009262300278623"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.10.007"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09714.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000450617"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2016.07.006"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14223"},{"key":"e_1_2_6_11_1","first-page":"51","article-title":"Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring?","volume":"7","author":"Singh MK","year":"2014","journal-title":"J Clin Aesthetic Dermatol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908127"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04037.x"},{"key":"e_1_2_6_14_1","first-page":"318","article-title":"The importance of physicians identifying and reporting adverse drug events","volume":"85","author":"Gatti JC","year":"2012","journal-title":"Am Fam Physician"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v6.i8.601"},{"key":"e_1_2_6_16_1","doi-asserted-by":"crossref","unstructured":"PoluzziE RaschiE PiccinniC De PontiF.Data mining techniques in pharmacovigilance: Analysis of the publicly accessible FDA Adverse Event Reporting System (AERS) [Internet]. InTech;2012. Available from:http:\/\/cdn.intechopen.com\/pdfs\/38579\/InTech-Data_mining_techniques_in_pharmacovigilance_analysis_of_the_publicly_accessible_fda_adverse_event_reporting_system_aers_pdf.","DOI":"10.5772\/50095"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-5364(13)60035-7"},{"key":"e_1_2_6_18_1","volume-title":"Handbook of Biological Statistics","author":"McDonald JH","year":"2014"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00563.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4823"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14728","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T22:14:00Z","timestamp":1694988840000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,21]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/jdv.14728"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14728","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,21]]}}}